Efficacy of the Royal Marsden Score (RMS) to improve the selection patients (pts) considered for participation to dose-seeking phase I trial.
Veronique Favre
No relevant relationships to disclose
Fatima-Zhora Meniai
No relevant relationships to disclose
Philippe Alexandre Cassier
No relevant relationships to disclose
Carlos Alberto Gomez-Roca
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose
Stephanie Clisant
No relevant relationships to disclose
Peggy Philippe
No relevant relationships to disclose
Alice Levart
No relevant relationships to disclose
Isabelle Desmoulins
No relevant relationships to disclose
Juliette Bouchet
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer; Janssen; Novartis; PharmaMar; Roche